Lipitor Lawsuit News: As Lipitor Diabetes Lawsuits Move Forward, Bernstein Liebhard LLP Comments on JAMA Editorial Expressing Concern about the "Statinization" of U.S.
NEW YORK, Dec. 9, 2013 /PRNewswire/ -- As Lipitor lawsuits (http://www.thelipitorlawsuit.com/ ) alleging use of the statin caused patients to develop Type 2 diabetes continue to move forward in U.S. courts, Bernstein Liebhard LLP notes that the Journal of the American Medical Association (JAMA) has published a new editorial that expresses concerns about the possible "statinazation" of the U.S. Its December 2nd publication follows the issuance of new guidelines last month by the American Heart Association and the American College of Cardiology that could increase the use of Lipitor and other statins by millions of patients.
(Logo: http://photos.prnewswire.com/prnh/20120202/MM47134LOGO)
Dr. John P. A. Ioannidis, director of the Stanford Prevention Research Center at Stanford University School of Medicine and author of the JAMA editorial, writes that the new guidelines could result in 40 million more Americans between the ages of 40 and 79 who do not have cardiovascular disease being prescribed statins. Among other things, Dr. Ioannidis points to the drugs' possible side effects, including diabetes and myopathy, and warns that the statinazation of America could "be one of the greatest achievements or one of the worst disasters of medical history."
"In light of the growing number of Lipitor diabetes lawsuits that have been filed in courts around the country, the concerns raised by Dr. Ioannidis merit further investigation. Patients considering statins, especially those who do not suffer from heart disease, should be fully apprised of their possible risks," says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to alleged victims of Lipitor and diabetes.
Lipitor Diabetes Lawsuits
In February 2012, the U.S. Food & Drug Administration (FDA) ordered Pfizer, Inc. to add new warnings to the Lipitor label regarding an increased risk of new-onset diabetes in patients who took the cholesterol-lowering statin. The FDA acted after research reported in JAMA: Internal Medicine the preceding month revealed that post-menopausal women treated with Lipitor may be at an increased risk for developing the disease.
A study published just this past May in the British Medical Journal added to growing Lipitor diabetes concerns, after it reported that patients taking Lipitor had a 22 percent higher risk of new-onset diabetes.
Since the FDA issued its warning in 2012, scores of Lipitor lawsuits have been filed in courts around the country by people who allege an association between Lipitor and diabetes. According to court documents, plaintiffs in Lipitor diabetes lawsuits have filed a petition with the U.S. Judicial Panel on Multidistrict Litigation seeking the consolidation of all federally-filed claims in a multidistrict litigation, and transfer of the cases to a single judge in one federal jurisdiction. However, Pfizer is opposed to the creation of a multidistrict litigation for federal Lipitor lawsuits. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502 (JPML))
Alleged victims of Lipitor diabetes may be entitled to compensation for medical bills, lost wages, pain and suffering and more. Find out more about the potential association between Lipitor and diabetes by visiting Bernstein Liebhard LLP's website. For a free, no obligation review of a potential Lipitor lawsuit, please call (888) 340-4807.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(888) 340-4807
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (888) 340-4807. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.thelipitorlawsuit.com/
https://plus.google.com/115936073311125306742?rel=author
SOURCE Bernstein Liebhard LLP
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article